These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38394987)

  • 1. Patterns of atrial fibrillation anticoagulation with rivaroxaban - 7-year follow-up from the Dresden NOAC registry.
    Tittl L; Marten S; Naue C; Beyer-Westendorf J
    Thromb Res; 2024 Apr; 236():61-67. PubMed ID: 38394987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
    Hecker J; Marten S; Keller L; Helmert S; Michalski F; Werth S; Sahin K; Tittl L; Beyer-Westendorf J
    Thromb Haemost; 2016 May; 115(5):939-49. PubMed ID: 26791999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry.
    Tittl L; Marten S; Naue C; Beyer-Westendorf J
    Thromb Res; 2021 Jun; 202():24-30. PubMed ID: 33711755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY.
    Köhler C; Tittl L; Marten S; Naue C; Spindler M; Stannek L; Fache K; Beyer-Westendorf J
    Thromb Res; 2022 Jul; 215():37-40. PubMed ID: 35623105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
    Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
    Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.
    Helmert S; Marten S; Mizera H; Reitter A; Sahin K; Tittl L; Beyer-Westendorf J
    J Thromb Thrombolysis; 2017 Aug; 44(2):169-178. PubMed ID: 28643004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
    Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
    JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
    Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry.
    Beyer-Westendorf J; Förster K; Ebertz F; Gelbricht V; Schreier T; Göbelt M; Michalski F; Endig H; Sahin K; Tittl L; Weiss N
    Europace; 2015 Apr; 17(4):530-8. PubMed ID: 25694537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study.
    Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
    Heart Vessels; 2019 Jan; 34(1):141-150. PubMed ID: 29980835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
    Laliberté F; Cloutier M; Nelson WW; Coleman CI; Pilon D; Olson WH; Damaraju CV; Schein JR; Lefebvre P
    Curr Med Res Opin; 2014 Jul; 30(7):1317-25. PubMed ID: 24650301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
    Halvorsen S; Johnsen SP; Madsen M; Linder M; Sulo G; Ghanima W; Gislason G; Hohnloser SH; Jenkins A; Al-Khalili F; Tell GS; Ehrenstein V
    Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):577-587. PubMed ID: 34244745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation.
    Kitazono T; Ikeda T; Ogawa S; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Cavaliere M; Hayashi Y; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Heart Vessels; 2020 Mar; 35(3):399-408. PubMed ID: 31492970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.
    Quinn GR; Hellkamp AS; Hankey GJ; Becker RC; Berkowitz SD; Breithardt G; Fava M; Fox KAA; Halperin JL; Mahaffey KW; Nessel CC; Patel MR; Piccini JP; Singer DE
    J Am Heart Assoc; 2018 Aug; 7(15):e008755. PubMed ID: 30371223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry.
    Caro Martinez C; Cerezo Manchado JJ; Flores Blanco PJ; Elvira Ruíz G; Albendín Iglesias H; Lova Navarro A; Arregui Montoya F; García Alberola A; Andrés Pascual Figal D; Bailén Lorenzo JL; Navarro-Almenzar B; García-Candel F; Manzano Fernández S
    Curr Med Res Opin; 2019 Aug; 35(8):1463-1471. PubMed ID: 30912682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.